Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening.

ABSTRACT:

Importance

In April 2017, the US Preventive Services Task Force (USPSTF) published a draft guideline that reversed its 2012 guidance advising against prostate-specific antigen (PSA)-based screening for prostate cancer in all men (grade D), instead endorsing individual decision-making for men aged 55 to 69 years (grade C).

Objective

To evaluate changes in rates of PSA testing after revisions in the USPSTF guideline on prostate cancer screening.

Design, setting, and participants

This retrospective cohort study used deidentified claims data from Blue Cross Blue Shield beneficiaries aged 40 to 89 years from January 1, 2013, through December 31, 2019.

Exposures

Publication of the USPSTF's draft (April 2017) and final (May 2018) recommendation on prostate cancer scre

SUBMITTER: Leapman MS 

PROVIDER: S-EPMC8587214 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature